Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 18 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
- 08 Mar 2016 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019 as reported by ClinicalTrials.gov record.